Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics has announced a research collaboration with The University of Texas MD Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA-based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.
Subscribe to our email newsletter
The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens.
Amir Avniel, president and CEO of Rosetta Genomics, said: “We believe that the experience we have in working with microRNA biomarkers, combined with MD Anderson’s extensive experience in lung cancer research, makes this a strong collaboration which may have a significant impact on the way lung cancer patients are diagnosed and treated.”